{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:26:11Z","timestamp":1793597171187,"version":"4.5.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40257-026-01078-3","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:32:10Z","timestamp":1792675930000},"page":"1239-1255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Evolving Landscape of Actinic Keratosis: Field Therapy, New Drugs, and Future Directions"],"prefix":"10.1007","volume":"27","author":[{"given":"Sonia P.","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adewunmi","family":"Adelaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-3478","authenticated-orcid":false,"given":"Vishal Anil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"issue":"1","key":"1078_CR1","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1038\/s41467-023-40822-9","volume":"14","author":"P Bailey","year":"2023","unstructured":"Bailey P, Ridgway RA, Cammareri P, Treanor-Taylor M, Bailey UM, Schoenherr C, et al. Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression. Nat Commun. 2023;14(1):5211. https:\/\/doi.org\/10.1038\/s41467-023-40822-9.","journal-title":"Nat Commun"},{"issue":"1","key":"1078_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65687-y","volume":"16","author":"B Tandukar","year":"2025","unstructured":"Tandukar B, Deivendran D, Chen L, Bandari AK, Cruz-Pacheco N, Sharma H, et al. Genetic evolution of keratinocytes to cutaneous squamous cell carcinoma. Nat Commun. 2025;16(1):10663. https:\/\/doi.org\/10.1038\/s41467-025-65687-y.","journal-title":"Nat Commun"},{"issue":"5","key":"1078_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/jamadermatol.2021.0372","volume":"157","author":"S Madani","year":"2021","unstructured":"Madani S, Marwaha S, Dusendang JR, Alexeeff S, Pham N, Chen EH, et al. Ten-year follow-up of persons with sun-damaged skin associated with subsequent development of cutaneous squamous cell carcinoma. JAMA Dermatol. 2021;157(5):559\u201365. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0372.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1078_CR4","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/j.jaad.2021.02.082","volume":"85","author":"DB Eisen","year":"2021","unstructured":"Eisen DB, Asgari MM, Bennett DD, Connolly SM, Dellavalle RP, Freeman EE, et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol. 2021;85(4):e209\u201333. https:\/\/doi.org\/10.1016\/j.jaad.2021.02.082.","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 5","key":"1078_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jdv.19559","volume":"38","author":"J Malvehy","year":"2024","unstructured":"Malvehy J, Stratigos AJ, Bagot M, Stockfleth E, Ezzedine K, Delarue A. Actinic keratosis: current challenges and unanswered questions. J Eur Acad Dermatol Venereol. 2024;38(suppl 5):3\u201311. https:\/\/doi.org\/10.1111\/jdv.19559.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1078_CR6","doi-asserted-by":"publisher","first-page":"13022","DOI":"10.1096\/fj.202001412R","volume":"34","author":"D Queen","year":"2020","unstructured":"Queen D, Shen Y, Trager MH, Lopez AT, Samie FH, Lewin JM, et al. UV biomarker genes for classification and risk stratification of cutaneous actinic keratoses and squamous cell carcinoma subtypes. FASEB J. 2020;34(9):13022\u201332. https:\/\/doi.org\/10.1096\/fj.202001412R.","journal-title":"FASEB J"},{"issue":"9","key":"1078_CR7","doi-asserted-by":"publisher","DOI":"10.15252\/msb.202211073","volume":"18","author":"L Sol\u00e9\u2010Boldo","year":"2022","unstructured":"Sol\u00e9\u2010Boldo L, Raddatz G, Gutekunst J, Gilliam O, Bormann F, Liberio MS, et al. Differentiation-related epigenomic changes define clinically distinct keratinocyte cancer subclasses. Mol Syst Biol. 2022;18(9):e11073. https:\/\/doi.org\/10.15252\/msb.202211073.","journal-title":"Mol Syst Biol"},{"issue":"3","key":"1078_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jamainternmed.2025.7281","volume":"186","author":"B Pecha","year":"2026","unstructured":"Pecha B, Shefler A, Markovitz AA, Billi AC. Do all actinic keratoses need treatment? Active surveillance as an option. JAMA Intern Med. 2026;186(3):277\u20138. https:\/\/doi.org\/10.1001\/jamainternmed.2025.7281.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"1078_CR9","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/bjd\/ljae437","volume":"192","author":"WG Philipp-Dormston","year":"2025","unstructured":"Philipp-Dormston WG, Br\u00fcckner M, Hoffmann M, Ba\u00e9 M, Fr\u00e4nken J, Gro\u00dfmann B, et al. Artificial daylight photodynamic therapy using methyl aminolaevulinate in a real-world setting in Germany: results from the noninterventional study ArtLight. Br J Dermatol. 2025;192(3):510\u20139. https:\/\/doi.org\/10.1093\/bjd\/ljae437.","journal-title":"Br J Dermatol"},{"key":"1078_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70556","author":"A Sj\u00f6holm","year":"2026","unstructured":"Sj\u00f6holm A, Backman E, Modin M, Fougelberg J, Claeson M, Paoli J. Simulated daylight versus conventional PDT for mild to moderate actinic keratoses: a randomized controlled trial. J Eur Acad Dermatol Venereol. 2026. https:\/\/doi.org\/10.1111\/jdv.70556.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1078_CR11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/ddg.15665","volume":"23","author":"I Oteiza\u2010Rius","year":"2025","unstructured":"Oteiza\u2010Rius I, Morell\u00f3\u2010Vicente A, Aguado\u2010Gil L, G\u00f3mez\u2010Gonz\u00e1lez EM, Marcos\u2010Mu\u00f1agorri D, Carrera\u2010Gabilondo A, et al. Combination of LED illumination and daylight photodynamic therapy for the treatment of actinic keratosis in solid organ transplant recipients: a prospective, randomized, comparative, intra-patient study. JDDG. 2025;23(6):713\u20138. https:\/\/doi.org\/10.1111\/ddg.15665.","journal-title":"JDDG"},{"issue":"3","key":"1078_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40257-023-00839-8","volume":"25","author":"I Aggarwal","year":"2024","unstructured":"Aggarwal I, Puyana C, Chandan N, Jetter N, Tsoukas M. Field cancerization therapies for the management of actinic keratosis: an updated review. Am J Clin Dermatol. 2024;25(3):391\u2013405. https:\/\/doi.org\/10.1007\/s40257-023-00839-8.","journal-title":"Am J Clin Dermatol"},{"key":"1078_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llag168","author":"V Lindholm","year":"2026","unstructured":"Lindholm V, Salmivuori M, Hahtola S, Salava A, Isoherranen K. Laser-assisted vs conventional daylight photodynamic therapies for actinic keratosis: a two-year randomized evaluator-blinded half-side comparative trial. Clin Exp Dermatol. 2026. https:\/\/doi.org\/10.1093\/ced\/llag168. (Published online April 15, 2026).","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"1078_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1684\/ejd.2026.5032","volume":"36","author":"N Ilina","year":"2026","unstructured":"Ilina N, M\u00fcller HH, L\u00f6ffler H. Skin physiology during daylight photodynamic therapy with additional fractional laser therapy. Eur J Dermatol. 2026;36(1):29\u201337. https:\/\/doi.org\/10.1684\/ejd.2026.5032.","journal-title":"Eur J Dermatol"},{"issue":"8","key":"1078_CR15","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1111\/jdv.20527","volume":"39","author":"A Tanew","year":"2024","unstructured":"Tanew A, Ristl R, Trattner H, Hacker V, Kroyer B, Radakovic S. Impact of light dose and fluence rate on the efficacy and tolerability of topical 5-ALA photodynamic therapy for actinic keratoses: a randomized, controlled, observer-blinded intrapatient comparison study. J Eur Acad Dermatol Venereol. 2024;39(8):1460\u20137. https:\/\/doi.org\/10.1111\/jdv.20527.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1078_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.70068","volume":"42","author":"TA Bullock","year":"2026","unstructured":"Bullock TA, Maytin EV. Painless photodynamic therapy: emerging protocols and light delivery systems for the treatment of actinic keratoses. Photodermatol Photoimmunol Photomed. 2026;42(1):e70068. https:\/\/doi.org\/10.1111\/phpp.70068.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"1078_CR17","unstructured":"DailyMed. KLISYRI (tirbanibulin) ointment, prescribing information. Updated November 8, 2024. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=589c8de8-b773-4d47-b60c-48471806cccc. Accessed 16 Jul 2026."},{"issue":"7","key":"1078_CR18","doi-asserted-by":"publisher","first-page":"19912s5","DOI":"10.36849\/JDD.19912","volume":"24","author":"C Jeong","year":"2025","unstructured":"Jeong C, Kircik L, Lebwohl M, Armstrong AW. Tirbanibulin 1% ointment: clinical trial and real-world evidence on efficacy, tolerability, safety, and patient-reported outcomes. J Drugs Dermatol. 2025;24(7):19912s5\u201312. https:\/\/doi.org\/10.36849\/JDD.19912.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1078_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.36849\/JDD.8264","volume":"23","author":"T Schlesinger","year":"2024","unstructured":"Schlesinger T, Kircik L, Lebwohl M, Patel VA, Berman B, Bhatia N, et al. Patient- and clinician-reported outcomes for tirbanibulin in actinic keratosis in clinical practice across the United States (PROAK). J Drugs Dermatol. 2024;23(5):338\u201346. https:\/\/doi.org\/10.36849\/JDD.8264.","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"1078_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2026.104632","volume":"117","author":"Y Gilaberte","year":"2026","unstructured":"Gilaberte Y, Y\u00e9lamos O, Ca\u00f1ueto J, Serra-Guill\u00e9n C, Conti A, Pajuelo F, et al. Patient- and clinician-reported outcomes, safety, and efficacy profile of tirbanibulin 1% for actinic keratosis under conditions close to routine clinical practice in Spain and Italy (TIRBASKIN Study). Actas Dermosifiliogr. 2026;117(7):104632. https:\/\/doi.org\/10.1016\/j.ad.2026.104632.","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"1078_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/ddg.15876","volume":"24","author":"MV Heppt","year":"2026","unstructured":"Heppt MV, Hadshiew I, Kempf A, Melzer A, Berking C. Real-world evidence of tirbanibulin in the treatment of actinic keratosis in Germany: prospective, multicenter, non-interventional KLIR study. J Dtsch Dermatol Ges. 2026;24(2):186\u201393. https:\/\/doi.org\/10.1111\/ddg.15876.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"1078_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ph19060954","volume":"19","author":"I Proietti","year":"2026","unstructured":"Proietti I, Coppolelli V, Taliano A, Colletti A, Cantisani C, Pellacani G, et al. Sequential keratolytic pre-treatment followed by tirbanibulin in hyperkeratotic actinic keratoses: a retrospective comparative study. Pharmaceuticals (Basel). 2026;19(6):954. https:\/\/doi.org\/10.3390\/ph19060954.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"1078_CR23","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/ijd.17168","volume":"63","author":"G Nazzaro","year":"2024","unstructured":"Nazzaro G, Carugno A, Bortoluzzi P, Buffon S, Astrua C, Zappia E, et al. Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients. Int J Dermatol. 2024;63(11):1566\u201374. https:\/\/doi.org\/10.1111\/ijd.17168.","journal-title":"Int J Dermatol"},{"issue":"9","key":"1078_CR24","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/1346-8138.17845","volume":"52","author":"F Li Pomi","year":"2025","unstructured":"Li Pomi F, d\u2019Aloja A, Rottura M, Vaccaro M, Borgia F. Tirbanibulin 1% ointment for the treatment of hyperkeratotic actinic keratosis. J Dermatol. 2025;52(9):1395\u2013403. https:\/\/doi.org\/10.1111\/1346-8138.17845.","journal-title":"J Dermatol"},{"issue":"3","key":"1078_CR25","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40257-022-00674-3","volume":"23","author":"L Del Regno","year":"2022","unstructured":"Del Regno L, Catapano S, Di Stefani A, Cappilli S, Peris K. A review of existing therapies for actinic keratosis: current status and future directions. Am J Clin Dermatol. 2022;23(3):339\u201352. https:\/\/doi.org\/10.1007\/s40257-022-00674-3.","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"1078_CR26","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40261-024-01392-w","volume":"44","author":"AH Dlott","year":"2024","unstructured":"Dlott AH, Spencer SA, Di Pasqua AJ. Calcipotriol and 5-fluorouracil combination therapy for the treatment of actinic keratosis in the clinic: a review article. Clin Drug Investig. 2024;44(10):733\u20137. https:\/\/doi.org\/10.1007\/s40261-024-01392-w.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1078_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI183274","volume":"135","author":"T Oka","year":"2025","unstructured":"Oka T, Smith SS, Son HG, Lee T, Oliver-Garcia VS, Mortaja M, et al. T helper 2 cell--directed immunotherapy eliminates precancerous skin lesions. J Clin Investig. 2025;135(1):e183274. https:\/\/doi.org\/10.1172\/JCI183274.","journal-title":"J Clin Investig"},{"issue":"1","key":"1078_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jaad.2026.03.088","volume":"95","author":"N Loranger","year":"2026","unstructured":"Loranger N, Trepanowski N, Shah P, Aizman L, DeSimone J, Cullison SJ, et al. Topical combined 5-fluorouracil and calcipotriene for actinic keratosis and superficial keratinocyte carcinoma: modified Delphi expert panel recommendations from ITSCC. J Am Acad Dermatol. 2026;95(1):112\u201320. https:\/\/doi.org\/10.1016\/j.jaad.2026.03.088.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1078_CR29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1056\/NEJMoa2024040","volume":"384","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, et al. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021;384(6):512\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2024040.","journal-title":"N Engl J Med"},{"key":"1078_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102143","volume":"47","author":"K Vats","year":"2021","unstructured":"Vats K, Kruglov O, Mizes A, Samovich SN, Amoscato AA, Tyurin VA, et al. Keratinocyte death by ferroptosis initiates skin inflammation after UVB exposure. Redox Biol. 2021;47:102143. https:\/\/doi.org\/10.1016\/j.redox.2021.102143.","journal-title":"Redox Biol"},{"issue":"3","key":"1078_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s43630-025-00691-1","volume":"24","author":"Y Teng","year":"2025","unstructured":"Teng Y, Huang Y, Tao X, Fan Y, You J. Emerging role of ferroptosis in ultraviolet radiation-driven skin photoaging: a narrative review. Photochem Photobiol Sci. 2025;24(3):531\u201342. https:\/\/doi.org\/10.1007\/s43630-025-00691-1.","journal-title":"Photochem Photobiol Sci"},{"issue":"1","key":"1078_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-025-05958-5","volume":"82","author":"K Duo","year":"2025","unstructured":"Duo K, Feng X, Tian X, Wang F, Zhao Y, Yu J, et al. Ferroptosis inhibitors: mechanisms of action and therapeutic potential. Cell Mol Life Sci. 2025;82(1):441. https:\/\/doi.org\/10.1007\/s00018-025-05958-5.","journal-title":"Cell Mol Life Sci"},{"key":"1078_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116721","volume":"277","author":"X Liu","year":"2024","unstructured":"Liu X, Guo Y, Huang Y, Wang Q, Huang Y, Lei Y, et al. GPX4 allosteric activators inhibit ferroptosis and exert myocardial protection in doxorubicin-induced myocardial injury mouse model. Eur J Med Chem. 2024;277:116721. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116721.","journal-title":"Eur J Med Chem"},{"issue":"3","key":"1078_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/10715762.2025.2475153","volume":"59","author":"H Wu","year":"2025","unstructured":"Wu H, Liao X, Huang W, Hu H, Lan L, Yang Q, et al. Examining the prognostic and clinicopathological significance of GPX4 in human cancers: a meta-analysis. Free Radic Res. 2025;59(3):239\u201349. https:\/\/doi.org\/10.1080\/10715762.2025.2475153.","journal-title":"Free Radic Res"},{"key":"1078_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1643235","volume":"15","author":"X Li","year":"2025","unstructured":"Li X, Zhu M, Dong R. Ferroptosis\u2019s master switch GPX4 emerges as universal biomarker for precision immunotherapy: a pan-cancer study with in vitro experiments validation. Front Oncol. 2025;15:1643235. https:\/\/doi.org\/10.3389\/fonc.2025.1643235.","journal-title":"Front Oncol"},{"issue":"5","key":"1078_CR36","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/s41556-026-01921-z","volume":"28","author":"M D\u2019Ambrosio","year":"2026","unstructured":"D\u2019Ambrosio M, White MEH, Gavriil ES, Bousset L, Birch J, Gruevska A, et al. Electrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability. Nat Cell Biol. 2026;28(5):915\u201329. https:\/\/doi.org\/10.1038\/s41556-026-01921-z.","journal-title":"Nat Cell Biol"},{"issue":"11","key":"1078_CR37","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/jdv.19289","volume":"37","author":"J Li","year":"2023","unstructured":"Li J, Xia Y, Kong S, Yang K, Chen H, Zhang Y, et al. Single-cell RNA-seq reveals actinic keratosis-specific keratinocyte subgroups and their crosstalk with secretory-papillary fibroblasts. J Eur Acad Dermatol Venereol. 2023;37(11):2273\u201383. https:\/\/doi.org\/10.1111\/jdv.19289.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1078_CR38","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/bjd\/ljad421","volume":"190","author":"L Calabrese","year":"2024","unstructured":"Calabrese L, Fiocco Z, Mellett M, Aoki R, Rubegni P, French LE, et al. Role of the NLRP1 inflammasome in skin cancer and inflammatory skin diseases. Br J Dermatol. 2024;190(3):305\u201315. https:\/\/doi.org\/10.1093\/bjd\/ljad421.","journal-title":"Br J Dermatol"},{"key":"1078_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104200","volume":"193","author":"A Zarezadeh Mehrabadi","year":"2024","unstructured":"Zarezadeh Mehrabadi A, Shahba F, Khorramdelazad H, Aghamohammadi N, Karimi M, Bagherzadeh K, et al. Interleukin-1 receptor accessory protein (IL-1RAP): a magic bullet candidate for immunotherapy of human malignancies. Crit Rev Oncol Hematol. 2024;193:104200. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104200.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"1078_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1001\/jamadermatol.2024.5750","volume":"161","author":"C Cox","year":"2025","unstructured":"Cox C, Brown S, Walpole E, Roy E, Dousset L, Ladwa R, et al. Immune checkpoint inhibitors in field cancerization and keratinocyte cancer prevention. JAMA Dermatol. 2025;161(4):383\u201390. https:\/\/doi.org\/10.1001\/jamadermatol.2024.5750.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1078_CR41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/mc.23464","volume":"62","author":"P Vaishampayan","year":"2023","unstructured":"Vaishampayan P, Curiel-Lewandrowski C, Dickinson SE. PD-L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer. Mol Carcinog. 2023;62(1):52\u201361. https:\/\/doi.org\/10.1002\/mc.23464.","journal-title":"Mol Carcinog"},{"issue":"6","key":"1078_CR42","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/jamadermatol.2025.0531","volume":"161","author":"E Wenande","year":"2025","unstructured":"Wenande E, Hastrup A, Wiegell S, Philipsen PA, Thomsen NB, Demehri S, et al. Human papillomavirus vaccination and actinic keratosis burden: the VAXAK randomized clinical trial. JAMA Dermatol. 2025;161(6):605\u201314. https:\/\/doi.org\/10.1001\/jamadermatol.2025.0531.","journal-title":"JAMA Dermatol"},{"key":"1078_CR43","unstructured":"ClinicalTrials.gov. Evaluate RLS-1496 topical cream for actinic keratosis. NCT07340697. Updated January 27, 2026. https:\/\/clinicaltrials.gov\/study\/NCT07340697. Accessed 16 Jul 2026."},{"issue":"1","key":"1078_CR44","doi-asserted-by":"publisher","first-page":"7650","DOI":"10.1038\/s41467-022-35345-8","volume":"13","author":"M Seviiri","year":"2022","unstructured":"Seviiri M, Law MH, Ong JS, Gharahkhani P, Fontanillas P, 23andMe Research Team, et al. A multi-phenotype analysis reveals 19 susceptibility loci for basal cell carcinoma and 15 for squamous cell carcinoma. Nat Commun. 2022;13(1):7650. https:\/\/doi.org\/10.1038\/s41467-022-35345-8.","journal-title":"Nat Commun"},{"issue":"6","key":"1078_CR45","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s00228-022-03299-x","volume":"78","author":"AC de Macedo Andrade","year":"2022","unstructured":"de Macedo Andrade AC, Felix FA, Fran\u00e7a GM, Ribeiro ILA, Barboza CAG, de Castro RD, et al. Hydrochlorothiazide use is associated with the risk of cutaneous and lip squamous cell carcinoma: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2022;78(6):919\u201330. https:\/\/doi.org\/10.1007\/s00228-022-03299-x.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1078_CR46","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1102a31","volume":"11","author":"A Sechi","year":"2021","unstructured":"Sechi A, di Altobrando A, Cerciello E, Maietti E, Patrizi A, Savoia F. Drug intake and actinic keratosis: a case-control study. Dermatol Pract Concept. 2021;11(2):e2021031. https:\/\/doi.org\/10.5826\/dpc.1102a31.","journal-title":"Dermatol Pract Concept"},{"issue":"5","key":"1078_CR47","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/bjd\/ljag016","volume":"194","author":"HJ Morgan","year":"2026","unstructured":"Morgan HJ, Deorukhkar RA, Tuckwell W, Shorning BY, Malladi N, Watkins WJ, et al. Presence of koilocytes in actinic keratosis identifies those at high risk of developing keratinocyte carcinoma. Br J Dermatol. 2026;194(5):914\u201322. https:\/\/doi.org\/10.1093\/bjd\/ljag016.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1078_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamadermatol.2022.4820","volume":"159","author":"\u00c1 G\u00f3mez-Tom\u00e1s","year":"2023","unstructured":"G\u00f3mez-Tom\u00e1s \u00c1, Bouwes Bavinck JN, Genders R, Gonz\u00e1lez-Cruz C, de Jong E, Arron S, et al. External validation of the Skin and UV Neoplasia Transplant Risk Assessment Calculator (SUNTRAC) in a large European solid organ transplant recipient cohort. JAMA Dermatol. 2023;159(1):29\u201336. https:\/\/doi.org\/10.1001\/jamadermatol.2022.4820.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1078_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41698-026-01302-7","volume":"10","author":"M Rodr\u00edguez-Paredes","year":"2026","unstructured":"Rodr\u00edguez-Paredes M, Feng Y, Gilliam O, Wegner K, Raddatz G, Gr\u00f6nniger E, et al. Non-invasive epidermis sampling for DNA methylation-based prediction of skin cancer phenotypes. NPJ Precis Oncol. 2026;10(1):89. https:\/\/doi.org\/10.1038\/s41698-026-01302-7.","journal-title":"NPJ Precis Oncol."},{"issue":"17","key":"1078_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172899","volume":"17","author":"C Soare","year":"2025","unstructured":"Soare C, Cozma EC, Giurc\u0103neanu C, Voiculescu VM. Comparative analysis of clinical, dermoscopic, and confocal microscopy scores for assessing severity of actinic keratosis. Cancers (Basel). 2025;17(17):2899. https:\/\/doi.org\/10.3390\/cancers17172899.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1078_CR51","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1201a31","volume":"12","author":"A Acar","year":"2022","unstructured":"Acar A, Karaarslan I. Comparison of actinic keratosis and severity index with physician global assessment and total lesion count and the ability to predict skin cancer. Dermatol Pract Concept. 2022;12(1):e2022031. https:\/\/doi.org\/10.5826\/dpc.1201a31.","journal-title":"Dermatol Pract Concept"},{"key":"1078_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-31259-9","volume":"16","author":"DA Ramos-Brice\u00f1o","year":"2026","unstructured":"Ramos-Brice\u00f1o DA, Pinto-Cuberos J, Linfante A, Wilkerson MG. Dermoscopically informed deep learning model for classification of actinic keratosis and cutaneous squamous cell carcinoma. Sci Rep. 2026;16:1381. https:\/\/doi.org\/10.1038\/s41598-025-31259-9.","journal-title":"Sci Rep"},{"key":"1078_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1770341","volume":"16","author":"Z Liu","year":"2026","unstructured":"Liu Z, Tang Y, He P, Long J, Chen Z, Wan M, et al. Clinical characteristics and local recurrence risk in patients with multiple actinic keratoses: a retrospective clinical data analysis. Front Oncol. 2026;16:1770341. https:\/\/doi.org\/10.3389\/fonc.2026.1770341.","journal-title":"Front Oncol"},{"issue":"5","key":"1078_CR54","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40257-018-0360-y","volume":"19","author":"CA Morton","year":"2018","unstructured":"Morton CA, Braathen LR. Daylight photodynamic therapy for actinic keratoses. Am J Clin Dermatol. 2018;19(5):647\u201356. https:\/\/doi.org\/10.1007\/s40257-018-0360-y.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1078_CR55","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1111\/ddg.15464","volume":"22","author":"G Balakirski","year":"2024","unstructured":"Balakirski G, Lehmann P, Szeimies RM, Hofmann SC. Photodynamic therapy in dermatology: established and new indications. J Dtsch Dermatol Ges. 2024;22(12):1651\u201362. https:\/\/doi.org\/10.1111\/ddg.15464.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"1078_CR56","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/DSS.0000000000000800","volume":"42","author":"DM Ozog","year":"2016","unstructured":"Ozog DM, Rkein AM, Fabi SG, Gold MH, Goldman MP, Lowe NJ, et al. Photodynamic therapy: a clinical consensus guide. Dermatol Surg. 2016;42(7):804\u201327. https:\/\/doi.org\/10.1097\/DSS.0000000000000800.","journal-title":"Dermatol Surg"},{"issue":"6","key":"1078_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13997","volume":"33","author":"C Queir\u00f3s","year":"2020","unstructured":"Queir\u00f3s C, Garrido PM, Maia Silva J, Filipe P. Photodynamic therapy in dermatology: beyond current indications. Dermatol Ther. 2020;33(6):e13997. https:\/\/doi.org\/10.1111\/dth.13997.","journal-title":"Dermatol Ther"},{"key":"1078_CR58","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.19459","volume":"104","author":"A Sj\u00f6holm","year":"2024","unstructured":"Sj\u00f6holm A, Claeson M, Paoli J, Heckemann B. Exploring patient pain experiences during and after conventional red light and simulated daylight photodynamic therapy for actinic keratosis: a qualitative interview study. Acta Derm Venereol. 2024;104:adv19459. https:\/\/doi.org\/10.2340\/actadv.v104.19459.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"1078_CR59","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/j.1365-2133.2012.10893.x","volume":"166","author":"K Togsverd-Bo","year":"2012","unstructured":"Togsverd-Bo K, Haak CS, Thaysen-Petersen D, Wulf HC, Anderson RR, H\u00e6dersdal M. Intensified photodynamic therapy of actinic keratoses with fractional CO2 laser: a randomized clinical trial. Br J Dermatol. 2012;166(6):1262\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10893.x.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1078_CR60","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jaad.2015.12.008","volume":"74","author":"M Haedersdal","year":"2016","unstructured":"Haedersdal M, Erlendsson AM, Paasch U, Anderson RR. Translational medicine in the field of ablative fractional laser (AFXL)-assisted drug delivery: a critical review from basics to current clinical status. J Am Acad Dermatol. 2016;74(5):981\u20131004. https:\/\/doi.org\/10.1016\/j.jaad.2015.12.008.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1078_CR61","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1001\/jamadermatol.2016.5268","volume":"153","author":"C Bay","year":"2017","unstructured":"Bay C, Lerche CM, Ferrick B, Philipsen PA, Togsverd-Bo K, Haedersdal M. Comparison of Physical Pretreatment Regimens to Enhance Protoporphyrin IX Uptake in Photodynamic Therapy: A Randomized Clinical Trial. JAMA Dermatol. 2017;153(4):270\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2016.5268.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1078_CR62","doi-asserted-by":"publisher","first-page":"502","DOI":"10.36849\/JDD.8638","volume":"24","author":"F Yousefian","year":"2025","unstructured":"Yousefian F, Ismaili A, Sachdeva S, Hammel J, Goodman M, Kircik L. The comparison between conventional photodynamic therapy and \u201cPainless\u201dTM photodynamic therapy in the treatment of actinic keratosis: a mini review. J Drugs Dermatol. 2025;24(5):502\u20136. https:\/\/doi.org\/10.36849\/JDD.8638.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"1078_CR63","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jaad.2019.09.010","volume":"82","author":"U Kaw","year":"2020","unstructured":"Kaw U, Ilyas M, Bullock T, Rittwage L, Riha M, Vidimos A, et al. A regimen to minimize pain during blue light photodynamic therapy of actinic keratoses: bilaterally controlled, randomized trial of simultaneous versus conventional illumination. J Am Acad Dermatol. 2020;82(4):862\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2019.09.010.","journal-title":"J Am Acad Dermatol"},{"key":"1078_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2025.104698","volume":"54","author":"JS Johnson","year":"2025","unstructured":"Johnson JS, Hanna J, Nowacki AS, Anand S, Shen AS, Maytin EV. Painless PDT using 10% aminolevulinate gel and red light: a pilot clinical trial of short-contact protocols to reduce discomfort during illumination. Photodiagnosis Photodyn Ther. 2025;54:104698. https:\/\/doi.org\/10.1016\/j.pdpdt.2025.104698.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"1","key":"1078_CR65","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-025-04327-9","volume":"40","author":"E Wenande","year":"2025","unstructured":"Wenande E, Wanner M, Sakamoto FH, Paasch U, Haedersdal M. The evolving landscape of laser-based skin cancer prevention. Lasers Med Sci. 2025;40(1):70. https:\/\/doi.org\/10.1007\/s10103-025-04327-9.","journal-title":"Lasers Med Sci"},{"issue":"7","key":"1078_CR66","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/lsm.23680","volume":"55","author":"E Trovato","year":"2023","unstructured":"Trovato E, Fiorani D, Cartocci A, Cinotti E, Rubegni P. IGF1 synthesis after CO2 fractional laser resurfacing (FLR): new insights in the treatment of scalp actinic keratoses. Lasers Surg Med. 2023;55(7):642\u201352. https:\/\/doi.org\/10.1002\/lsm.23680.","journal-title":"Lasers Surg Med"},{"key":"1078_CR67","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.addr.2020.01.001","volume":"153","author":"AM Erlendsson","year":"2020","unstructured":"Erlendsson AM, Olesen UH, Haedersdal M, Rossi AM. Ablative fractional laser-assisted treatments for keratinocyte carcinomas and its precursors-Clinical review and future perspectives. Adv Drug Deliv Rev. 2020;153:185\u201394. https:\/\/doi.org\/10.1016\/j.addr.2020.01.001.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"1078_CR68","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/lsm.70119","volume":"58","author":"LMO Salviano","year":"1927","unstructured":"Salviano LMO, Hirayama AB, Pincelli MS, Arruda VN, Davan\u00e7o RC, Pinto LR, et al. Clinical and histopathological assessment of the field of cancerization in human skin before and after treatment with a 1927-nm thulium fractional laser. Lasers Surg Med. 1927;58(4):311\u201320. https:\/\/doi.org\/10.1002\/lsm.70119.","journal-title":"Lasers Surg Med"},{"issue":"7","key":"1078_CR69","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/lsm.70043","volume":"57","author":"PM Friedman","year":"2025","unstructured":"Friedman PM, Dover JS, Chapas A, Jacobson A. Current trends and future directions of the dual 1550-nm erbium glass fiber and 1927-nm thulium fiber non-ablative fractional laser system. Lasers Surg Med. 2025;57(7):561\u201370. https:\/\/doi.org\/10.1002\/lsm.70043.","journal-title":"Lasers Surg Med"},{"issue":"3","key":"1078_CR70","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/lsm.70108","volume":"58","author":"MP Goldman","year":"2026","unstructured":"Goldman MP, Wu DC, Khetarpal S, Jacobson A, Wang JV, Geronemus RG. Dual 1550-nm erbium glass fiber and 1927-nm thulium fiber non-ablative fractional laser system treatment in patients with skin of color: a review of clinical studies and unmet needs. Lasers Surg Med. 2026;58(3):169\u201379. https:\/\/doi.org\/10.1002\/lsm.70108.","journal-title":"Lasers Surg Med"},{"issue":"3","key":"1078_CR71","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/jdv.16844","volume":"35","author":"T Steeb","year":"2021","unstructured":"Steeb T, Koch EAT, Wessely A, Wiest LG, Schmitz L, Berking C, et al. Chemical peelings for the treatment of actinic keratosis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(3):641\u20139. https:\/\/doi.org\/10.1111\/jdv.16844.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1078_CR72","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1097\/DSS.0000000000003144","volume":"47","author":"AJ Jiang","year":"2021","unstructured":"Jiang AJ, Soon SL, Rullan P, Brody HJ, Monheit GD, Lee KC. Chemical peels as field therapy for actinic keratoses: a systematic review. Dermatol Surg. 2021;47(10):1343\u20136. https:\/\/doi.org\/10.1097\/DSS.0000000000003144.","journal-title":"Dermatol Surg"},{"key":"1078_CR73","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: squamous cell skin cancer. Version 2.2026. Published February 2026. Accessed 16 Jul 2026."},{"issue":"12","key":"1078_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/biom14121512","volume":"14","author":"R Belardi","year":"2024","unstructured":"Belardi R, Pacifici F, Cosio T, Lambiase S, Shumak RG, Artosi F, et al. Role of nicotinamide in the pathogenesis of actinic keratosis: implications for NAD+\/SIRT1 pathway. Biomolecules. 2024;14(12):1512. https:\/\/doi.org\/10.3390\/biom14121512.","journal-title":"Biomolecules"},{"issue":"7","key":"1078_CR75","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/ced\/llag073","volume":"51","author":"A Susanto","year":"2026","unstructured":"Susanto A, Morgan E, Lindsay D, Collins LG. Chemoprevention of keratinocyte carcinomas and actinic keratoses in adults who were immunocompetent: a systematic review. Clin Exp Dermatol. 2026;51(7):1202\u201312. https:\/\/doi.org\/10.1093\/ced\/llag073.","journal-title":"Clin Exp Dermatol"},{"issue":"9","key":"1078_CR76","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJMoa2203086","volume":"388","author":"NC Allen","year":"2023","unstructured":"Allen NC, Martin AJ, Snaidr VA, Eggins R, Chong AH, Fernand\u00e9z-Pe\u00f1as P, et al. Nicotinamide for skin-cancer chemoprevention in transplant recipients. N Engl J Med. 2023;388(9):804\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2203086.","journal-title":"N Engl J Med"},{"issue":"10","key":"1078_CR77","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1001\/jamadermatol.2020.2327","volume":"156","author":"DM Schauder","year":"2020","unstructured":"Schauder DM, Kim J, Nijhawan RI. Evaluation of the use of capecitabine for the treatment and prevention of actinic keratoses, squamous cell carcinoma, and basal cell carcinoma: a systematic review. JAMA Dermatol. 2020;156(10):1117\u201324. https:\/\/doi.org\/10.1001\/jamadermatol.2020.2327.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1078_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/ph16121686","volume":"16","author":"E Campione","year":"2023","unstructured":"Campione E, Rivieccio A, Gaeta Shumak R, Costanza G, Cosio T, Lambiase S, et al. Preliminary evidence of efficacy, safety, and treatment satisfaction with tirbanibulin 1% ointment: a clinical perspective on actinic keratoses. Pharmaceuticals (Basel). 2023;16(12):1686. https:\/\/doi.org\/10.3390\/ph16121686.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"10","key":"1078_CR79","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1056\/NEJMoa1811850","volume":"380","author":"MHE Jansen","year":"2019","unstructured":"Jansen MHE, Kessels JPHM, Nelemans PJ, Kouloubis N, Arits AHMM, van Pelt HPA, et al. Randomized trial of four treatment approaches for actinic keratosis. N Engl J Med. 2019;380(10):935\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1811850.","journal-title":"N Engl J Med"},{"issue":"1","key":"1078_CR80","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1172\/JCI89820","volume":"127","author":"TJ Cunningham","year":"2017","unstructured":"Cunningham TJ, Tabacchi M, Eliane JP, Tuchayi SM, Manivasagam S, Mirzaalian H, et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest. 2017;127(1):106\u201316. https:\/\/doi.org\/10.1172\/JCI89820.","journal-title":"J Clin Invest"},{"issue":"1","key":"1078_CR81","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-34524-z","volume":"16","author":"Y Tian","year":"2026","unstructured":"Tian Y, Yao Y, Zhang J. Comparison of the efficacy of photodynamic therapy and imiquimod cream in patients with actinic keratosis: a systematic review and meta-analysis. Sci Rep. 2026;16(1):4370. https:\/\/doi.org\/10.1038\/s41598-025-34524-z.","journal-title":"Sci Rep"},{"issue":"6","key":"1078_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061133","volume":"16","author":"L Bernal Masferrer","year":"2024","unstructured":"Bernal Masferrer L, Gracia Caza\u00f1a T, Bernad Alonso I, \u00c1lvarez-Salafranca M, Almenara Blasco M, Gallego Rentero M, et al. Topical immunotherapy for actinic keratosis and field cancerization. Cancers. 2024;16(6):1133. https:\/\/doi.org\/10.3390\/cancers16061133.","journal-title":"Cancers"},{"issue":"4","key":"1078_CR83","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2165\/00128071-200708040-00002","volume":"8","author":"H Zhan","year":"2007","unstructured":"Zhan H, Zheng H. The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: treatment and prevention. Am J Clin Dermatol. 2007;8(4):195\u2013200. https:\/\/doi.org\/10.2165\/00128071-200708040-00002.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1078_CR84","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12800","volume":"32","author":"GJ Thomas","year":"2019","unstructured":"Thomas GJ, Herranz P, Cruz SB, Parodi A. Treatment of actinic keratosis through inhibition of cyclooxygenase-2: potential mechanism of action of diclofenac sodium 3% in hyaluronic acid 2.5%. Dermatol Ther. 2019;32(3):e12800. https:\/\/doi.org\/10.1111\/dth.12800.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1078_CR85","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/jdv.70069","volume":"40","author":"U Reinhold","year":"2026","unstructured":"Reinhold U, Leitz N, Dominicus R, Szab\u00f3 EL, Dirschka T, Popp G, et al. KOH 5% solution versus diclofenac 3% for the treatment of actinic keratosis: results from a three-armed RCT. J Eur Acad Dermatol Venereol. 2026;40(6):1050\u20138. https:\/\/doi.org\/10.1111\/jdv.70069.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1078_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15124553","volume":"15","author":"G Gualdi","year":"2026","unstructured":"Gualdi G, Soligon G, Silvetti P, Balestra L, Bertolla D, Fania L, et al. Sequential field therapy in actinic keratosis: a mechanism-based rationale for complementary treatment strategies. J Clin Med. 2026;15(12):4553. https:\/\/doi.org\/10.3390\/jcm15124553.","journal-title":"J Clin Med"},{"issue":"3","key":"1078_CR87","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/14737159.2022.2049243","volume":"22","author":"G Durante","year":"2022","unstructured":"Durante G, Broseghini E, Comito F, Naddeo M, Milani M, Salamon I, et al. Circulating microRNA biomarkers in melanoma and non-melanoma skin cancer. Expert Rev Mol Diagn. 2022;22(3):305\u201318. https:\/\/doi.org\/10.1080\/14737159.2022.2049243.","journal-title":"Expert Rev Mol Diagn"},{"key":"1078_CR88","doi-asserted-by":"publisher","first-page":"adv6229","DOI":"10.2340\/actadv.v103.6229","volume":"103","author":"C Morton","year":"2023","unstructured":"Morton C, Baharlou S, Basset-Seguin N, Calzavara-Pinton P, Dirschka T, Gilaberte Y, et al. Expert recommendations on facilitating personalized approaches to long-term management of actinic keratosis: the Personalizing Actinic Keratosis Treatment (PAKT) Project. Acta Derm Venereol. 2023;103:adv6229. https:\/\/doi.org\/10.2340\/actadv.v103.6229.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1078_CR89","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/DSS.0000000000003677","volume":"49","author":"N Lampley 3rd","year":"2023","unstructured":"Lampley N 3rd, Rigo R, Schlesinger T, Rossi AM. Field therapy for actinic keratosis: a structured review of the literature on efficacy, cost, and adherence. Dermatol Surg. 2023;49(2):124\u20139. https:\/\/doi.org\/10.1097\/DSS.0000000000003677.","journal-title":"Dermatol Surg"},{"issue":"4","key":"1078_CR90","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bjd.17435","volume":"180","author":"MV Heppt","year":"2019","unstructured":"Heppt MV, Steeb T, Ruzicka T, Berking C. Cryosurgery combined with topical interventions for actinic keratosis: a systematic review and meta-analysis. Br J Dermatol. 2019;180(4):740\u20138. https:\/\/doi.org\/10.1111\/bjd.17435.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1078_CR91","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.jaad.2025.07.060","volume":"93","author":"A Morell\u00f3-Vicente","year":"2025","unstructured":"Morell\u00f3-Vicente A, Oteiza-Rius I, G\u00f3mez-Gonz\u00e1lez EM, Carrera-Gabilondo A, Marcos-Mu\u00f1agorri D, Anto\u00f1anzas-P\u00e9rez J, et al. Efficacy and safety of sequential treatment with cryotherapy followed by 1% topical tirbanibulin for actinic keratoses in organ transplant recipients: a randomized clinical trial. J Am Acad Dermatol. 2025;93(6):1441\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2025.07.060.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1078_CR92","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/bjd.20974","volume":"187","author":"ZU Hasan","year":"2022","unstructured":"Hasan ZU, Ahmed I, Matin RN, Homer V, Lear JT, Ismail F, et al. Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments). Br J Dermatol. 2022;187(3):324\u201337. https:\/\/doi.org\/10.1111\/bjd.20974.","journal-title":"Br J Dermatol"},{"issue":"21","key":"1078_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216312","volume":"13","author":"M Hyeraci","year":"2024","unstructured":"Hyeraci M, Pistore G, Ricci F, Moro F, Lella GD, Dellambra E, et al. Cost-effectiveness analysis of topical treatments for actinic keratosis in Italian National Health System. J Clin Med. 2024;13(21):6312. https:\/\/doi.org\/10.3390\/jcm13216312.","journal-title":"J Clin Med"},{"issue":"6","key":"1078_CR94","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1001\/jamadermatol.2022.1034","volume":"158","author":"S Ahmady","year":"2022","unstructured":"Ahmady S, Jansen MHE, Nelemans PJ, Kessels JPHM, Arits AHMM, de Rooij MJM, et al. Risk of invasive cutaneous squamous cell carcinoma after different treatments for actinic keratosis: a secondary analysis of a randomized clinical trial. JAMA Dermatol. 2022;158(6):634\u201340. https:\/\/doi.org\/10.1001\/jamadermatol.2022.1034.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1078_CR95","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jaad.2022.05.051","volume":"87","author":"B Cheng","year":"2022","unstructured":"Cheng B, Veerabagu S, Miller CJ, Sobanko JF, Shin TM, Higgins HW 2nd, et al. A comparison of invasive squamous cell carcinoma greater than 1 year after treatment with 5-fluorouracil, imiquimod, or photodynamic therapy with aminolevulinic acid. J Am Acad Dermatol. 2022;87(3):592\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2022.05.051.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1078_CR96","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000548336","volume":"242","author":"P Calzavara-Pinton","year":"2026","unstructured":"Calzavara-Pinton P, Arisi M, Bettolini L, Rovaris S, Maione V, Soglia S, et al. Management of all patients with multiple actinic keratoses requires lifelong follow-up and repeated treatment cycles: a 12-year prospective observational study of a cohort of 81 patients. Dermatology. 2026;242(1):49\u201357. https:\/\/doi.org\/10.1159\/000548336.","journal-title":"Dermatology"},{"issue":"3","key":"1078_CR97","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamadermatol.2019.4212","volume":"156","author":"KA Reynolds","year":"2020","unstructured":"Reynolds KA, Schlessinger DI, Vasic J, Iyengar S, Qaseem Y, Behshad R, et al. Core outcome set for actinic keratosis clinical trials. JAMA Dermatol. 2020;156(3):326\u201333. https:\/\/doi.org\/10.1001\/jamadermatol.2019.4212.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"1078_CR98","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2021.2779","volume":"157","author":"T Steeb","year":"2021","unstructured":"Steeb T, Wessely A, Petzold A, Brinker TJ, Schmitz L, Leiter U, et al. Evaluation of long-term clearance rates of interventions for actinic keratosis: a systematic review and network meta-analysis. JAMA Dermatol. 2021;157(9):1066\u201377. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2779.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1078_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18040708","volume":"18","author":"G Pistore","year":"2026","unstructured":"Pistore G, Ambrosio L, Di Guardo A, Panebianco AR, Di Lella G, Conforti C, et al. Non-invasive assessment of treatment response in actinic keratosis: a clinically oriented multimodal review. Cancers. 2026;18(4):708. https:\/\/doi.org\/10.3390\/cancers18040708.","journal-title":"Cancers"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01078-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01078-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01078-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:26:12Z","timestamp":1793593572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01078-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":99,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1078"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01078-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SG, AA, and VP declare that they have no relevant conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed during the current study.","order":2,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to literature search and manuscript drafting and review. All authors read and approved the final version.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During preparation of this article, the authors used OpenAI ChatGPT and Anthropic Claude to assist with drafting support and proofreading. All AI-assisted output was reviewed, verified, and revised by the authors, who take full responsibility for the final manuscript content.","order":8,"name":"Ethics","label":"Use of Artificial Intelligence Tools","group":{"name":"EthicsHeading","label":"Declarations"}}]}}